Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Research Areas

- Tool Development
- Basic Research

At a Glance

- Status: Active Consortium
- Year Launched: 2012
- Initiating Organization: Innovative Medicines Initiative
- Initiator Type: Government
- Location: Europe

Abstract

Many new medicines are based on biological molecules such as proteins, peptides, or nucleic acids. The goal of the Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT) project is to shed new light on the obstacles these drugs (which are known as biopharmaceuticals) need to overcome to get to where they are needed in the body. The team will then use this information to develop and validate biopharmaceutical formulations to deliver these novel drugs to their targets. The program duration is set at 60 months.

Mission

COMPACT’s overall objective is to reduce delivery and targeting bottlenecks for developing novel, innovative, biopharmaceutical-based medicines.

Consortium History
Nov. 1, 2012: COMPACT was officially launched.

**Structure & Governance**

The COMPACT team is coordinated by Sanofi, GSK, and Universiteit Utrecht.

**Financing**

COMPACT is funded by the Innovative Medicines Initiative (IMI; €10.2 million) as well as the European Federation of Pharmaceutical Industries and Associations (€16.6 million in kind, including €1.6 million of non-European Union contributions), and academic institutions and other contributors (€3.2 million). The list of funders can be found at http://www.imi.europa.eu/sites/default/files/uploads/projects/documents/factsheets/COMPACT_funding_per_participant.pdf

**Intellectual Property**

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk[AT]imi.europa.eu. The IMI IP policy can be accessed at http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

**Data Sharing**

In keeping with IMI policy, the COMPACT project has up to one year after completion to disseminate IP or data created by the project.

**Impact/Accomplishment**
COMPACT believes that biopharmaceuticals have the potential to improve the lives of patients with diseases and conditions that are currently hard or even impossible to treat. By finding more effective ways of administering these drugs, and improving their ability to travel through the body to where they are needed, COMPACT will enable more patients to benefit from biopharmaceuticals. Furthermore, designing less-invasive administration routes and reducing the dose (and therefore the side effects) and frequency of administration will help to improve patient compliance with treatments.

The 2013 award for Hungarian Young Entrepreneur of the Year was won by Tamas Letoha, chief executive officer of Pharmacoidea, which is a partner in two IMI projects: COMPACT and AETIONOMY.

**Links/Social Media Feed**

Homepage  
http://www.compact-research.org/

Other website  
http://www.imi.europa.eu/content/compact

**Points of Contact**

Ekkehard Leberer  
Sanofi-Aventis Deutschland GmbH  
phone: +49 69 305 18998  
email: Ekkehard.Leberer@sanofi.com

Enrico Mastrobattista  
Universiteit Utrecht  
phone: +31 6 22736567  
email: e.mastrobattista@uu.nl

**Sponsors & Partners**

Abbott GmbH & CoKG

Bioneer A/S
Boehringer Ingelheim International GmbH
Cardiff University
GlaxoSmithKline Research and Development Ltd.
Helmholtz-Zentrum für Infektionsforschung GmbH
Helsingin Yliopisto
Ludwig-Maximilians-Universität München
Merck KGaA
Norges Teknisk-Naturvitenskapelige Universitet NTNU
Novo Nordisk A/S
Pfizer Limited
Pharmacoidea Development and Service Ltd
Sanofi-Aventis Deutschland GmbH
Stockholms Universitet
Universität Wien
Universität Zurich
Universiteit Gent
Universiteit Leiden
Universiteit Utrecht
University of Copenhagen
University of Oxford

Updated: 04/14/2016